Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice

Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes

“…Another real-life study investigated the effects of two commonly prescribed sulphonylureas on kidney outcomes in 4486 T2DM patients treated with either glimepiride or gliclazide for > 2 years and followed for a median duration of 4.7 years [47]. In a matched cohort using propensity scores with 12,122 person-years of follow-up, there was no significant difference between the two sulphonylureas in risk of ESRD or doubling of creatinine, although there was a trend towards higher risks in the glimepiride group than in the gliclazide group, reaching statistical significance in some subgroups [47].…”

Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease

“…52 No evidence of renoprotective effects such as decreasing albuminuria or delaying DKD progression has been recognized as attributable to SUs. 53 The reports to be exposed in June 2019 of the CAROLINA trial will provide evidence of long-term outcomes of glimepiride vs linagliptin considering cardiovascular as primary and renal as secondary endpoints. 54 Besides their glucose-lowering effects, some GLP-1-RAs show benefit in cardiovascular outcomes (CVOT).…”

Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies

“…The baseline median duration of diabetes varied from 0 to 29 years. Two studies [29,47] recruited study participants at the time of diabetes diagnosis, but 13 studies did not report the baseline duration of diabetes [12,13,27,36,40,50,56,57,71,74,77,78,81]. Characteristics of the 71 included studies are presented in Table S1.…”